title: A fluorescence-based thermal shift assay identifies inhibitors of mitogen activated protein kinase kinase 4.
abstract: Prostate cancer (PCa) is the second highest cause of cancer death in United States males. If the metastatic movement of PCa cells could be inhibited, then mortality from PCa could be greatly reduced. Mitogen-activated protein kinase kinase 4 (MAP2K4) has previously been shown to activate pro-invasion signaling pathways in human PCa. Recognizing that MAP2K4 represents a novel and validated therapeutic target, we sought to develop and characterize an efficient process for the identification of small molecules that target MAP2K4. Using a fluorescence-based thermal shift assay (FTS) assay, we first evaluated an 80 compound library of known kinase inhibitors, thereby identifying 8 hits that thermally stabilized MAP2K4 in a concentration dependent manner. We then developed an in vitro MAP2K4 kinase assay employing the biologically relevant downstream substrates, JNK1 and p38 MAPK, to evaluate kinase inhibitory function. In this manner, we validated the performance of our initial FTS screen. We next applied this approach to a 2000 compound chemically diverse library, identified 7 hits, and confirmed them in the in vitro kinase assay. Finally, by coupling our structure-activity relationship data to MAP2K4's crystal structure, we constructed a model for ligand binding. It predicts binding of our identified inhibitory compounds to the ATP binding pocket. Herein we report the creation of a robust inhibitor-screening platform with the ability to inform the discovery and design of new and potent MAP2K4 inhibitors.
authors: Department of Medicine, Northwestern University, Chicago, Illinois, United States of America.
authors: Sankar N
authors: SN
authors: Krishna
authors: Chi-Hao
authors: CH
authors: Luan
authors: Rama K
authors: RK
authors: Mishra
authors: Li
authors: L
authors: Xu
authors: Karl A
authors: KA
authors: Scheidt
authors: Wayne F
authors: WF
authors: Anderson
authors: Raymond C
authors: RC
authors: Bergan
mesh_terms: D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004795:Enzyme Stability / Q000187:drug effects; D005470:Fluorometry / Q000379:methods*; D057166:High-Throughput Screening Assays; D006801:Humans; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D054852:Small Molecule Libraries / Q000494:pharmacology; D013696:Temperature
chemical_list: D047428:Protein Kinase Inhibitors; D054852:Small Molecule Libraries; D048670:MAP Kinase Kinase 4